PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023
Summary
Rheumatoid arthritis (RA) is a chronic autoimmune disease which causes inflammation and deformity of the joints . It affects over seven million individuals in the 10MM covered in this report (US, France, Germany, Italy, Spain, UK, Japan, Australia, China, and India) and the prevalence is expected to grow to just over 8.5 million individuals by 2023. The anti-TNFs have been effective in treating the signs and symptoms of RA and inhibiting progression to erosive bone disease. However, the landscape is quickly changing with the introduction of biosimilars, novel biologics, and a class of oral therapies known as JAK inhibitors, all of which will change the market dynamics between 2013 and 2023. With the anti-TNFs as extremely effective therapies for RA, the market is extremely competitive for new entrants and will undergo further pressure as biosimilars are approved and launch.
Highlights
Key Questions Answered
- How large an impact will biosimilars have on the RA market? What do rheumatologists and key opinion leaders across the 10MM think about the evolving RA treatment landscape?
- How is the uptake of JAK inhibitors expected to affect the global RA market?
- Which novel biologics are the most promising? How are product launches expected to affect the anti-TNFs?
- According to KOLs, what are the most important unmet needs in RA? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2023?
- What governmental and industry developments are likely to affect sales of the top-selling RA drugs in the markets researched? Which is the largest growth market globally?
Key Findings
- Biosimilars are expected to change the landscape for RA and create pricing pressure in the RA market. However, questions from physicians and regulators regarding the appropriate use of biosimilars still lingers.
- Sales of anti-TNFs are expected to decline due to the introduction of biosimilars and other novel biologics and small molecules to treat RA.
- Developers of pipeline products will need strong clinical data and a clear development and commercialization strategy to penetrate the competitive RA market.
- The market will continue to be dominated by Big Pharma who will leverage their R&D, manufacturing, and distribution networks.
Scope
- Overview of rheumatoid arthritis (RA), including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations.
- Annualized RA market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the RA biologics and biosimilars markets.
- Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically JAK inhibitors (such as Eli Lilly/Incyte’s baricitinib), novel biologics (such as AstraZeneca-MedImmune’s mavrilimumab), and biosimilars (such as Celltrion/Hospira/Alvogen’s Inflectra/Remsima).
- Analysis of the current and future market competition in the global RA market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the RA market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global RA market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the global RA market from 2013-2023.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table Of Contents
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 25
2 Introduction 28
2.1 Catalyst 28
2.2 Related Reports 29
2.3 Upcoming Related Reports 29
3 Disease Overview 30
3.1 Etiology and Pathophysiology 30
3.1.1 Etiology 30
3.1.2 Pathophysiology 30
3.2 Symptoms 35
3.3 Prognosis 36
3.4 Quality of Life 36
4 Epidemiology 37
4.1 Disease Background 37
4.2 Risk Factors and Comorbidities 37
4.3 Global Trends 39
4.3.1 US 39
4.3.2 5EU 40
4.3.3 Japan 41
4.3.4 Australia 41
4.3.5 China 42
4.3.6 India 42
4.4 Forecast Methodology 42
4.4.1 Sources Used 45
4.4.2 Sources Not Used 49
4.4.3 Forecast Assumptions and Methods - Total Prevalent Cases of RA 50
4.4.4 Forecast Assumptions and Methods - Diagnosed Prevalent Cases of RA 54
4.5 Epidemiological Forecast for RA (2013-2023) 55
4.5.1 Total Prevalent Cases of RA 55
4.5.2 Age-Specific Total Prevalent Cases of RA 57
4.5.3 Sex-Specific Total Prevalent Cases of RA 59
4.5.4 Diagnosed Prevalent Cases of RA 61
4.5.5 Age-Standardized Diagnosed Prevalence of RA 63
4.6 Discussion 65
4.6.1 Epidemiological Forecast Insight 65
4.6.2 Limitations of the Analysis 65
4.6.3 Strengths of the Analysis 66
5 Disease Management 67
5.1 Diagnosis and Treatment Overview 67
5.1.1 Diagnosis 67
5.1.2 Treatment Guidelines 69
5.1.3 Leading Prescribed Drugs for the Treatment of RA 78
5.1.4 Clinical Practice 79
5.2 US 84
5.3 France 88
5.4 Germany 89
5.5 Italy 92
5.6 Spain 94
5.7 UK 95
5.8 Japan 99
5.9 Australia 101
5.10 China 103
5.11 India 105
6 Competitive Assessment 108
6.1 Overview 108
6.2 Product Profiles - Major Brands 109
6.2.1 Enbrel (etanercept) 109
6.2.2 Humira (adalimumab) 116
6.2.3 Remicade (infliximab) 120
6.2.4 Simponi (golimumab) 126
6.2.5 Cimzia (certolizumab pegol) 132
6.2.6 Orencia (abatacept) 136
6.2.7 Actemra/RoActemra (tocilizumab) 142
6.2.8 Rituxan/MabThera (rituximab) 150
6.2.9 Inflectra/Remsima (infliximab biosimilar) 155
6.2.10 Xeljanz (tofacitinib) 158
6.2.11 Iguratimod/T-614 165
6.2.12 Methotrexate (Numerous Brands) 169
6.3 Biosimilars 172
6.3.1 Introduction 172
6.3.2 Hospira’s Inflectra Versus J&J’s Remicade in Key Autoimmune Diseases 174
6.3.3 Biosimilars in the Immunology Community 174
6.3.4 By the Numbers: Biosimilars in Development 175
6.3.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry 179
6.3.6 Uptake of Biosimilars for RA is Expected to Vary by Market 180
6.3.7 Biosimilars’ Forecast 183
6.4 Other Therapies 191
7 Unmet Need and Opportunity 193
7.1 Overview 193
7.2 Development of Cost-Effective Therapies 194
7.2.1 Unmet Need 194
7.2.2 Gap Analysis 195
7.2.3 Opportunity 195
7.3 Biomarkers to Predict Responsiveness to Therapy 196
7.3.1 Unmet Need 196
7.3.2 Gap Analysis 198
7.3.3 Opportunity 198
7.4 Early Diagnosis of RA 199
7.4.1 Unmet Need 199
7.4.2 Gap Analysis 200
7.4.3 Opportunity 201
7.5 Personalized Treatment Approach 202
7.5.1 Unmet Need 202
7.5.2 Gap Analysis 202
7.5.3 Opportunity 204
8 Pipeline Assessment 206
8.1 Overview 206
8.2 Clinical Trial Mapping 206
8.2.1 Clinical Trials by Class 206
8.3 Promising Drugs in Clinical Development 208
8.3.1 Sarilumab 215
8.3.2 Sirukumab 223
8.3.3 Clazakizumab 230
8.3.4 Cosentyx (secukinumab) 236
8.3.5 Tregalizumab 242
8.3.6 Mavrilimumab 248
8.3.7 Denosumab (Prolia/Xgeva) 253
8.3.8 Baricitinib 259
8.3.9 Peficitinib 269
8.3.10 Decernotinib 275
8.3.11 Filgotinib 281
8.3.12 Masitinib 287
8.3.13 RAVAX 294
8.4 Other Drugs in Development 299
9 Current and Future Players 302
9.1 Trends in Corporate Strategy 305
9.2 Company Profiles 306
9.2.1 AbbVie 306
9.2.2 Pfizer 308
9.2.3 Amgen 311
9.2.4 Johnson & Johnson 314
9.2.5 Eli Lilly 316
9.2.6 Bristol-Myers Squibb 318
9.2.7 UCB 320
9.2.8 Roche 321
9.2.9 GlaxoSmithKline 323
9.2.10 Novartis 325
9.2.11 Sanofi 327
9.2.12 AstraZeneca- MedImmune 329
9.2.13 Astellas 331
9.2.14 Vertex 333
9.2.15 Daiichi Sankyo 335
10 Market Outlook 338
10.1 Global Markets 338
10.1.1 Forecast 338
10.1.2 Drivers and Barriers - Global Issues 343
10.2 United States 345
10.2.1 Forecast 345
10.2.2 Key Events 351
10.2.3 Drivers and Barriers 352
10.3 France 354
10.3.1 Forecast 354
10.3.2 Key Events 359
10.3.3 Drivers and Barriers 359
10.4 Germany 362
10.4.1 Forecast 362
10.4.2 Key Events 367
10.4.3 Drivers and Barriers 368
10.5 Italy 371
10.5.1 Forecast 371
10.5.2 Key Events 376
10.5.3 Drivers and Barriers 376
10.6 Spain 378
10.6.1 Forecast 378
10.6.2 Key Events 384
10.6.3 Drivers and Barriers 385
10.7 United Kingdom 387
10.7.1 Forecast 387
10.7.2 Key Events 393
10.7.3 Drivers and Barriers 393
10.8 Japan 396
10.8.1 Forecast 396
10.8.2 Key Events 401
10.8.3 Drivers and Barriers 401
10.9 Australia 404
10.9.1 Forecast 404
10.9.2 Key Events 409
10.9.3 10.9.3 Drivers and Barriers 409
10.10 China 411
10.10.1 Forecast 411
10.10.2 Key Events 416
10.10.3 Drivers and Barriers 416
10.11 India 418
10.11.1 Forecast 418
10.11.2 Key Events 423
10.11.3 Drivers and Barriers 423
11 Appendix 426
11.1 Bibliography 426
11.2 Abbreviations 452
11.3 Methodology 459
11.4 Forecasting Methodology 459
11.4.1 Diagnosed RA Patients 459
11.4.2 Percentage of Drug-Treated Patients 460
11.4.3 Drugs Included in Each Therapeutic Class 460
11.4.4 Launch and Patent Expiry Dates 461
11.4.5 General Pricing Assumptions 462
11.4.6 Individual Drug Assumptions 464
11.4.7 Generic and Biosimilar Erosion 476
11.4.8 Pricing of Pipeline Agents 476
11.5 Primary Research - KOLs Interviewed for This Report 479
11.6 Primary Research - Prescriber Survey 481
11.7 About the Authors 481
11.7.1 Analyst 481
11.7.2 Reviewer 482
11.7.3 Therapy Area Director 482
11.7.4 Epidemiologist 483
11.7.5 Global Head of Healthcare 484
11.8 About GlobalData 485
11.9 Disclaimer 485
List Of Tables
1.1 List of Tables
Table 1: Symptoms of RA 35
Table 2: Risk Factors and Comorbidities for RA 39
Table 3: 1987 ACR Diagnostic Criteria for RA 43
Table 4: 10MM, Sources of RA Prevalence Data 44
Table 5: 8MM, Total Prevalent Cases of RA, Ages ?18 Years, Both Sexes, N, Selected Years 2013-2023 56
Table 6: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N (Row %), 2013 58
Table 7: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ?18 Years, N (Row %), 2013 60
Table 8: 10MM, Diagnosed Prevalent Cases of RA, Ages ?18 Years, Both Sexes, N, Selected Years 2013-2023 62
Table 9: 1987 ACR Diagnostic Criteria for RA 68
Table 10: 2010 ACR/EULAR Diagnostic Criteria for RA 69
Table 11: Treatment Guidelines for RA Used by Each Country in the 10MM 71
Table 12: ACR 2012 Criteria for RA Remission and Low/Moderate/High Disease Activity 74
Table 13: EULAR 2013 Criteria for RA Remission 75
Table 14: Most Prescribed Biologics for RA (After csDMARDs) in the Global Markets, 2014 79
Table 15: RA Treatment Country Profile - US 87
Table 16: RA Treatment Country Profile - France 89
Table 17: RA Treatment Country Profile - Germany 91
Table 18: RA Treatment Country Profile - Italy 93
Table 19: RA Treatment Country Profile - Spain 95
Table 20: RA Treatment Country Profile - UK 98
Table 21: RA Treatment Country Profile - Japan 100
Table 22: RA Treatment Country Profile - Australia 103
Table 23: RA Treatment Country Profile - China 105
Table 24: RA Treatment Country Profile - India 107
Table 25: Leading Branded Treatments for RA 2014 109
Table 26: Product Profile - Enbrel 111
Table 27: 10-Year, Open-Label Safety and Efficacy Trial of Enbrel: Efficacy Results at 11 Years for Completers 112
Table 28: 10-year, Open-Label Safety and Efficacy Trial of Enbrel: Overall Safety Results 113
Table 29: Enbrel SWOT Analysis, 2014 114
Table 30: Global Sales Forecasts ($m) for Enbrel, 2013-2023 115
Table 31: Product Profile - Humira 117
Table 32: Humira SWOT Analysis, 2014 119
Table 33: Global Sales Forecasts ($m) for Humira, 2013-2023 120
Table 34: Product Profile - Remicade 122
Table 35: Remicade SWOT Analysis, 2014 125
Table 36: Global Sales Forecasts ($m) for Remicade, 2013-2023 126
Table 37: Product Profile - Simponi 128
Table 38: Simponi SWOT Analysis, 2014 130
Table 39: Global Sales Forecasts ($m) for Simponi, 2013-2023 131
Table 40: Product Profile - Cimzia 133
Table 41: Cimzia SWOT Analysis, 2014 135
Table 42: Global Sales Forecasts ($m) for Cimzia, 2013-2023 136
Table 43: Product Profile - Orencia 138
Table 44: Orencia SWOT Analysis, 2014 141
Table 45: Global Sales Forecasts ($m) for Orencia, 2013-2023 142
Table 46: Product Profile - Actemra 146
Table 47: Actemra SWOT Analysis, 2014 148
Table 48: Global Sales Forecasts ($m) for Actemra, 2013-2023 149
Table 49: Product Profile - Rituxan 152
Table 50: Rituxan SWOT Analysis, 2014 153
Table 51: Global Sales Forecasts ($m) for Rituxan, 2013-2023 154
Table 52: Product Profile - Inflectra/Remsima 156
Table 53: Inflectra/Remsima SWOT Analysis, 2014 157
Table 54: Product Profile - Xeljanz 161
Table 55: ORAL Standard ACR20 Responses for Tofacitinib vs. Humira and Placebo at Month 6 162
Table 56: ORAL Step ACR20, 50, and 70 Responses for Xeljanz vs. Placebo at Month 6 162
Table 57: Xeljanz SWOT Analysis, 2014 164
Table 58: Global Sales Forecasts ($m) for Xeljanz, 2013-2023 165
Table 59: Product Profile - Iguratimod 166
Table 60: Iguratimod SWOT Analysis, 2014 167
Table 61: Global Sales Forecasts ($m) for Iguratimod, 2013-2023 168
Table 62: Product Profile - MTX 170
Table 63: MTX SWOT Analysis, 2014 171
Table 64: Global Sales Forecasts ($m) for MTX, 2013-2023 172
Table 65: Biosimilars Pipeline for RA, 2013 176
Table 66: Physician Uptake of Biosimilar Products for RA Across the 10MM, 2014 183
Table 67: Global Sales Forecasts ($m) for Etanercept Biosimilars, 2013-2023 183
Table 68: Global Sales Forecasts ($m) for Adalimumab Biosimilars, 2013-2023 184
Table 69: Global Sales Forecasts ($m) for Infliximab Biosimilars, 2013-2023 186
Table 70: Global Sales Forecasts ($m) for Certolizumab Pegol Biosimilars, 2013-2023 187
Table 71: Global Sales Forecasts ($m) for Abatacept Biosimilars, 2013-2023 188
Table 72: Global Sales Forecasts ($m) for Tocilizumab Biosimilars, 2013-2023 189
Table 73: Global Sales Forecasts ($m) for Rituximab Biosimilars, 2013-2023 190
Table 74: Summary of Minor Therapeutic Drug Classes Used to Treat RA, 2014 192
Table 75: Unmet Need and Opportunity in RA, 2014 194
Table 76: Comparison of Therapeutic Drug Classes in Development for RA, 2014 215
Table 77: Product Profile - Sarilumab 217
Table 78: MOBILITY Study Part, A, Results for Sarilumab at Week 12 218
Table 79: MOBILITY Study, Part B, Results for Sarilumab at Week 52 218
Table 80: Sarilumab SWOT Analysis, 2014 222
Table 81: Global Sales Forecasts ($m) for Sarilumab, 2013-2023 223
Table 82: Product Profile - Sirukumab 224
Table 83: Sirukumab SWOT Analysis, 2014 228
Table 84: Global Sales Forecasts ($m) for Sirukumab, 2013-2023 229
Table 85: Product Profile - Clazakizumab 231
Table 86: Phase IIb Study of Clazakizumab: ACR Responses After 12 Weeks 232
Table 87: Phase IIb Study of Clazakizumab: ACR Responses After 24 Weeks 232
Table 88: Clazakizumab SWOT Analysis, 2014 235
Table 89: Global Sales Forecasts ($m) for Clazakizumab, 2013-2023 236
Table 90: Product Profile - Cosentyx 238
Table 91: Cosentyx SWOT Analysis, 2014 241
Table 92: Global Sales Forecasts ($m) for Cosentyx, 2013-2023 242
Table 93: Product Profile - Tregalizumab 244
Table 94: Tregalizumab SWOT Analysis, 2014 247
Table 95: Global Sales Forecasts ($m) for Tregalizumab, 2013-2023 247
Table 96: Product Profile - Mavrilimumab 249
Table 97: Mavrilimumab SWOT Analysis, 2014 252
Table 98: Global Sales Forecasts ($m) for Mavrilimumab, 2013-2023 253
Table 99: Product Profile - Denosumab 255
Table 100: Denosumab SWOT Analysis, 2014 258
Table 101: Global Sales Forecasts ($m) for denosumab in RA, 2013-2023 259
Table 102: Product Profile - Baricitinib 261
Table 103: Baricitinib Phase IIb Trial, Part A: ACR Responses at Week 12 262
Table 104: Baricitinib Phase IIb Trial, Part B: ACR Responses at Weeks 24 and 52 262
Table 105: Baricitinib Phase IIb Trial, Part A: Safety at Week 12 264
Table 106: Baricitinib Phase IIb Trial, Part A, Laboratory Values at Week 12 264
Table 107: Baricitinib SWOT Analysis, 2014 267
Table 108: Global Sales Forecasts ($m) for Baricitinib, 2013-2023 268
Table 109: Product Profile - Peficitinib 270
Table 110: Peficitinib SWOT Analysis, 2014 274
Table 111: Global Sales Forecasts ($m) for Peficitinib, 2013-2023 275
Table 112: Product Profile - Decernotinib 276
Table 113: Phase IIb tudy of Decernotinib: ACR Responses at Week 24 277
Table 114: Decernotinib SWOT Analysis, 2014 280
Table 115: Global Sales Forecasts ($m) for Decernotinib, 2013-2023 281
Table 116: Product Profile - Filgotinib 282
Table 117: Filgotinib SWOT Analysis, 2014 286
Table 118: Global Sales Forecasts ($m) for Filgotinib, 2013-2023 287
Table 119: Product Profile - Masitinib 289
Table 120: ACR Response to Masitinib in RA (12 Weeks) 290
Table 121: ACR Responses for Masitinib in the Phase IIa ITT Population (12-82 Weeks) 290
Table 122: Masitinib SWOT Analysis, 2014 293
Table 123: Global Sales Forecasts ($m) for Masitinib, 2013-2023 294
Table 124: Product Profile - RAVAX 295
Table 125: RAVAX SWOT Analysis, 2014 298
Table 126: Drugs in Phase II of Development for RA, 2014 300
Table 127: Key Companies in the RA Market, 2014 304
Table 128: AbbVie’s RA Portfolio Assessment, 2014 307
Table 129: Pfizers’s RA Portfolio Assessment, 2014 310
Table 130: Amgen’s RA Portfolio Assessment, 2014 313
Table 131: J&J’s RA Portfolio Assessment, 2014 315
Table 132: Eli Lilly’s RA Portfolio Assessment, 2014 317
Table 133: BMS’ RA Portfolio Assessment, 2014 319
Table 134: UCB’s RA Portfolio Assessment, 2014 320
Table 135: Roche’s RA Portfolio Assessment, 2014 322
Table 136: GSK’s RA Portfolio Assessment, 2014 324
Table 137: Novartis’ RA Portfolio Assessment, 2014 326
Table 138: Sanofi’s RA Portfolio Assessment, 2014 328
Table 139: AstraZeneca -MedImmune’s RA Portfolio Assessment, 2014 330
Table 140: Astellas’s RA Portfolio Assessment, 2014 332
Table 141: Vertex’s RA Portfolio Assessment, 2014 334
Table 142: Daiichi Sankyo’s RA Portfolio Assessment, 2014 336
Table 143: Global Sales Forecasts ($m) for RA, 2013-2023 340
Table 144: Global RA Market - Drivers and Barriers, 2013-2023 343
Table 145: Sales Forecasts ($m) for RA in the United States, 2013-2023 348
Table 146: Key Events Impacting Sales for RA in the US, 2013-2023 351
Table 147: RA Market in the US - Drivers and Barriers, 2013-2023 352
Table 148: Sales Forecasts ($m) for RA in France, 2013-2023 356
Table 149: Key Events Impacting Sales for RA in France, 2013-2023 359
Table 150: RA Market in France - Drivers and Barriers, 2013-2023 359
Table 151: Sales Forecasts ($m) for RA in Germany, 2013-2023 364
Table 152: Key Events Impacting Sales for RA in Germany, 2013-2023 367
Table 153: RA Market in Germany - Drivers and Barriers, 2013-2023 368
Table 154: Sales Forecasts ($m) for RA in Italy, 2013-2023 373
Table 155: Key Events Impacting Sales for RA in Italy, 2013-2023 376
Table 156: RA Market in Italy - Drivers and Barriers, 2013-2023 376
Table 157: Sales Forecasts ($m) for RA in Spain, 2013-2023 381
Table 158: Key Events Impacting Sales for RA in Spain, 2013-2023 384
Table 159: RA Market in Spain - Drivers and Barriers, 2013-2023 385
Table 160: Sales Forecasts ($m) for RA in the UK, 2013-2023 390
Table 161: Key Events Impacting Sales for RA in the UK, 2013-2023 393
Table 162: RA Market in the UK - Drivers and Barriers, 2013-2023 393
Table 163: Sales Forecasts ($m) for RA in Japan, 2013-2023 398
Table 164: Key Events Impacting Sales for RA in Japan, 2013-2023 401
Table 165: RA Market in Japan - Drivers and Barriers, 2013-2023 401
Table 166: Sales Forecasts ($m) for RA in Australia, 2013-2023 406
Table 167: Key Events Impacting Sales for RA in Australia, 2013-2023 409
Table 168: RA Market in Australia - Drivers and Barriers, 2013-2023 409
Table 169: Sales Forecasts ($) for RA in China, 2013-2023 413
Table 170: Key Events Impacting Sales for RA in China, 2013-2023 416
Table 171: RA Market in China - Drivers and Barriers, 2013-2023 416
Table 172: Sales Forecasts ($m) for RA in India, 2013-2023 420
Table 173: Key Events Impacting Sales for RA in India, 2013-2023 423
Table 174: RA Market in India - Drivers and Barriers, 2013-2023 423
Table 175: Key Launch Dates of RA Products in the 10MM 461
Table 176: Key Patent Expiries 462
Table 177: High-Prescribing Physicians (non-KOLs) Surveyed, By Country 481
List Of Figures
1.2 List of Figures
Figure 1: Normal Synovial Joint and Synovial Joint with RA 31
Figure 2: Cellular and Cytokine Targets for the Current RA Drugs 34
Figure 3: 8MM, Total Prevalent Cases of RA, Ages ?18 Years, Both Sexes, N, 2013-2023 57
Figure 4: 8MM, Age-Specific Total Prevalent Cases of RA, Both Sexes, N, 2013 59
Figure 5: 8MM, Sex-Specific Total Prevalent Cases of RA, Ages ?18 Years, N, 2013 61
Figure 6: 10MM, Diagnosed Prevalent Cases of RA, Ages ?18 Years, Both Sexes, N, 2013-2023 63
Figure 7: 10MM, Age-Standardized Prevalence of RA (%), Ages ?18 Years, 2013 64
Figure 8: Disease Management Flowchart for Early RA - ACR 2012 75
Figure 9: Disease Management Flowchart for Established RA - ACR 2012 76
Figure 10: Flowchart for the Management of RA - EULAR 2013 77
Figure 11: Biosimilar Prescribing Habits in RA Across the 10MM, 2014 182
Figure 12: Global Sales Forecasts ($m) for Enbrel vs. Etanercept Biosimilars, 2013-2023 184
Figure 13: Global Sales Forecasts ($m) for Humira vs. Adalimumab Biosimilars, 2013-2023 185
Figure 14: Global Sales Forecasts ($m) for Remicade vs. Infliximab Biosimilars, 2013-2023 187
Figure 15: Global Sales Forecasts ($m) for Cimzia vs. Certolizumab Pegol Biosimilars, 2013-2023 188
Figure 16: Global Sales of Orencia vs. Abatacept (IV) Biosimilars, 2013-2023 189
Figure 17: Global Sales of Actemra vs. Tocilizumab (IV) Biosimilars, 2013-2023 190
Figure 18: Global Sales of Rituxan vs. Rituximab Biosimilars, 2013-2023 191
Figure 19: RA Clinical Trials - By Drug Class, 2014 208
Figure 20: RA - Phase II-III Pipeline, 2014 210
Figure 21: Competitive Assessment of Late-Stage Pipeline Agents in RA, 2013-2023 214
Figure 22: Clinical and Commercial Positioning of Sarilumab 221
Figure 23: Clinical and Commercial Positioning of Sirukumab 228
Figure 24: Clinical and Commercial Positioning of Clazakizumab 235
Figure 25: Clinical and Commercial Positioning of Cosentyx 240
Figure 26: Clinical and Commercial Positioning of Tregalizumab 246
Figure 27: Clinical and Commercial Positioning of Mavrilimumab 252
Figure 28: Clinical and Commercial Positioning of denosumab in RA 258
Figure 29: Clinical and Commercial Positioning of Baricitinib 267
Figure 30: Clinical and Commercial Positioning of Peficitinib 273
Figure 31: Clinical and Commercial Positioning of Decernotinib 279
Figure 32: Clinical and Commercial Positioning of Filgotinib 285
Figure 33: Clinical and Commercial Positioning of Masitinib 292
Figure 34: Clinical and Commercial Positioning of RAVAX 298
Figure 35: Company Portfolio Gap Analysis in RA, 2013-2023 305
Figure 36: AbbVie SWOT Analysis in RA, 2013-2023 308
Figure 37: Pfizer SWOT Analysis in RA, 2013-2023 311
Figure 38: Amgen SWOT Analysis in RA, 2013-2023 313
Figure 39: J&J SWOT Analysis in RA, 2013-2023 316
Figure 40: Eli Lilly SWOT Analysis in RA, 2013-2023 318
Figure 41: BMS SWOT Analysis in RA, 2013-2023 319
Figure 42: UCB SWOT Analysis in RA, 2013-2023 321
Figure 43: Roche SWOT Analysis in RA, 2013-2023 323
Figure 44: GSK SWOT Analysis in RA, 2013-2023 325
Figure 45: Novartis SWOT Analysis in RA, 2013-2023 327
Figure 46: Sanofi SWOT Analysis in RA, 2013-2023 329
Figure 47: AstraZeneca/MedImmune SWOT Analysis in RA, 2013-2023 331
Figure 48: Astellas SWOT Analysis in RA, 2013-2023 333
Figure 49: Vertex SWOT Analysis in RA, 2013-2023 335
Figure 50: Daiichi Sankyo SWOT Analysis in RA, 2013-2023 337
Figure 51: Global Sales for RA by Region, 2013-2023 342
Figure 52: Sales for RA in the United States by Drug Class, 2013-2023 350
Figure 53: Sales for RA in France by Drug Class, 2013-2023 358
Figure 54: Sales for RA in Germany by Drug Class, 2013-2023 366
Figure 55: Sales for RA in Italy by Drug Class, 2013-2023 375
Figure 56: Sales for RA in Spain by Drug Class, 2013-2023 383
Figure 57: Sales for RA in the UK by Drug Class, 2013-2023 392
Figure 58: Sales for RA in Japan by Drug Class, 2013-2023 400
Figure 59: Sales for RA in Australia by Drug Class, 2013-2023 408
Figure 60: Sales for RA in China by Drug Class, 2013-2023 415
Figure 61: Sales for RA in India by Drug Class, 2013-2023 422
